Transglutaminase is a Tumor Cell and Cancer Stem Cell Survival Factor

Overview

Journal Mol Carcinog

Specialties Molecular Biology
Oncology

Date 2015 Aug 11

PMID 26258961

Citations 63

Authors

Richard L Eckert

Matthew L Fisher

Dan Grun

Gautam Adhikary

Wen Xu

Candace Kerr

Affiliations

Soon will be listed here.

Abstract

Recent studies indicate that cancer cells express elevated levels of type II transglutaminase (TG2), and that expression is further highly enriched in cancer stem cells derived from these cancers. Moreover, elevated TG2 expression is associated with enhanced cancer stem cell marker expression, survival signaling, proliferation, migration, invasion, integrin-mediated adhesion, epithelial-mesenchymal transition, and drug resistance. TG2 expression is also associated with formation of aggressive and metastatic tumors that are resistant to conventional therapeutic intervention. This review summarizes the role of TG2 as a cancer cell survival factor in a range of tumor types, and as a target for preventive and therapeutic intervention. The literature supports the idea that TG2, in the closed/GTP-binding/signaling conformation, drives cancer cell and cancer stem cell survival, and that TG2, in the open/crosslinking conformation, is associated with cell death.

Citing Articles

Transglutaminase 2 in breast cancer metastasis and drug resistance.

Li M, Wang X, Hong J, Mao J, Chen J, Chen X Front Cell Dev Biol. 2024; 12:1485258.

PMID: 39544364 PMC: 11560871. DOI: 10.3389/fcell.2024.1485258.

A Marine Collagen-Based 3D Scaffold for In Vitro Modeling of Human Prostate Cancer Niche and Anti-Cancer Therapeutic Discovery.

Song W, Lim Y, Kim J, Kang H, Lee C, Rajbongshi L Mar Drugs. 2024; 22(7).

PMID: 39057404 PMC: 11277582. DOI: 10.3390/md22070295.

A bioprinted sea-and-island multicellular model for dissecting human pancreatic tumor-stroma reciprocity and adaptive metabolism.

Li M, Freeman S, Franco-Barraza J, Cai K, Kim A, Jin S Biomaterials. 2024; 310:122631.

PMID: 38815457 PMC: 11186049. DOI: 10.1016/j.biomaterials.2024.122631.

Membrane Association of the Short Transglutaminase Type 2 Splice Variant (TG2-S) Modulates Cisplatin Resistance in a Human Hepatocellular Carcinoma (HepG2) Cell Line.

Meshram D, Fanutti C, Pike C, Coussons P Curr Issues Mol Biol. 2024; 46(5):4251-4270.

PMID: 38785527 PMC: 11119602. DOI: 10.3390/cimb46050259.

Conformational Modulation of Tissue Transglutaminase via Active Site Thiol Alkylating Agents: Size Does Not Matter.

Navals P, Rangaswamy A, Kasyanchyk P, Berezovski M, Keillor J Biomolecules. 2024; 14(4).

PMID: 38672511 PMC: 11048362. DOI: 10.3390/biom14040496.

References

Bergamini C . GTP modulates calcium binding and cation-induced conformational changes in erythrocyte transglutaminase. FEBS Lett. 1988; 239(2):255-8. DOI: 10.1016/0014-5793(88)80928-1. View

Verma A, Guha S, Wang H, Fok J, Koul D, Abbruzzese J . Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin Cancer Res. 2008; 14(7):1997-2005. DOI: 10.1158/1078-0432.CCR-07-1533. View

Verma A, Guha S, Diagaradjane P, Kunnumakkara A, Sanguino A, Lopez-Berestein G . Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res. 2008; 14(8):2476-83. DOI: 10.1158/1078-0432.CCR-07-4529. View

Takaku K, Futamura M, Saitoh S, Takeuchi Y . Tissue-type transglutaminase is not a tumor-related marker. J Biochem. 1995; 118(6):1268-70. DOI: 10.1093/oxfordjournals.jbchem.a125017. View

Auersperg N, Wong A, Choi K, Kang S, Leung P . Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001; 22(2):255-88. DOI: 10.1210/edrv.22.2.0422. View

Takahashi H, Isobe T, Horibe S, Takagi J, Yokosaki Y, Sheppard D . Tissue transglutaminase, coagulation factor XIII, and the pro-polypeptide of von Willebrand factor are all ligands for the integrins alpha 9beta 1 and alpha 4beta 1. J Biol Chem. 2000; 275(31):23589-95. DOI: 10.1074/jbc.M003526200. View

Pincelli C, Marconi A . Keratinocyte stem cells: friends and foes. J Cell Physiol. 2010; 225(2):310-5. DOI: 10.1002/jcp.22275. View

Li C, Heidt D, Dalerba P, Burant C, Zhang L, Adsay V . Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67(3):1030-7. DOI: 10.1158/0008-5472.CAN-06-2030. View

Dyer L, Schooler K, Ai L, Klop C, Qiu J, Robertson K . The transglutaminase 2 gene is aberrantly hypermethylated in glioma. J Neurooncol. 2010; 101(3):429-40. PMC: 3019272. DOI: 10.1007/s11060-010-0277-7. View

10.

Facchiano F, DArcangelo D, Riccomi A, Lentini A, Beninati S, Capogrossi M . Transglutaminase activity is involved in polyamine-induced programmed cell death. Exp Cell Res. 2001; 271(1):118-29. DOI: 10.1006/excr.2001.5356. View

11.

Gundemir S, Colak G, Tucholski J, Johnson G . Transglutaminase 2: a molecular Swiss army knife. Biochim Biophys Acta. 2011; 1823(2):406-19. PMC: 3265640. DOI: 10.1016/j.bbamcr.2011.09.012. View

12.

Pavlyukov M, Antipova N, Balashova M, Shakhparonov M . Detection of Transglutaminase 2 conformational changes in living cell. Biochem Biophys Res Commun. 2012; 421(4):773-9. DOI: 10.1016/j.bbrc.2012.04.082. View

13.

Yuan L, Holmes T, Watts R, Khosla C, Broekelmann T, Mecham R . Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas. J Neurooncol. 2010; 103(2):207-19. PMC: 3732656. DOI: 10.1007/s11060-010-0379-2. View

14.

Di Giacomo G, Lentini A, Beninati S, Piacentini M, Rodolfo C . In vivo evaluation of type 2 transglutaminase contribution to the metastasis formation in melanoma. Amino Acids. 2008; 36(4):717-24. DOI: 10.1007/s00726-008-0119-5. View

15.

Yakubov B, Chelladurai B, Schmitt J, Emerson R, Turchi J, Matei D . Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer. Neoplasia. 2013; 15(6):609-19. PMC: 3664993. DOI: 10.1593/neo.121878. View

16.

Xu L, Begum S, Hearn J, Hynes R . GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci U S A. 2006; 103(24):9023-8. PMC: 1474142. DOI: 10.1073/pnas.0602681103. View

17.

Ischenko I, Seeliger H, Schaffer M, Jauch K, Bruns C . Cancer stem cells: how can we target them?. Curr Med Chem. 2008; 15(30):3171-84. DOI: 10.2174/092986708786848541. View

18.

Fisher M, Keillor J, Xu W, Eckert R, Kerr C . Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival. Mol Cancer Res. 2015; 13(7):1083-94. PMC: 4504806. DOI: 10.1158/1541-7786.MCR-14-0685-T. View

19.

Cao L, Petrusca D, Satpathy M, Nakshatri H, Petrache I, Matei D . Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis. 2008; 29(10):1893-900. PMC: 2556973. DOI: 10.1093/carcin/bgn158. View

20.

van Groningen J, Klink S, Bloemers H, Swart G . Expression of tissue-type transglutaminase correlates positively with metastatic properties of human melanoma cell lines. Int J Cancer. 1995; 60(3):383-7. DOI: 10.1002/ijc.2910600319. View